LEHI, Utah and LOUISVILLE, Ky., June 23, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced the results of a commissioned study conducted by Forrester Consulting on behalf of Waystar revealing that AI is becoming mission-critical in revenue cycle management (RCM) because of its proven impact and measurable return on investment.
The study, "AI in Healthcare Payments Software: A Strategic Imperative," shows that 82% of healthcare leaders now consider AI integral to their RCM operations, with 70% identifying it as a top organizational priority. The study also found that AI is delivering significant improvements in key revenue cycle metrics, including claim accuracy, denial prevention, workforce efficiency, and payment speed, signaling a sharp acceleration in healthcare's AI adoption curve.
"This research reinforces what we're seeing across the industry. AI is no longer theoretical and is fundamentally reshaping how providers operate," said Matt Hawkins, CEO of Waystar. "As healthcare organizations navigate growing complexity, the study shows they're relying on proven and trusted RCM software providers to deploy AI."
Key findings include:
Based on responses from more than 300 healthcare leaders, the study shows that providers are prioritizing strategic AI implementation, especially in payer-facing workflows such as prior authorizations and denial appeals. The research points to a broader shift as AI delivers measurable impact across organizations of all sizes, accelerating automation, enhancing analytics, improving accuracy, and driving stronger returns on investment.
To view the full study, visit waystar.com/aistudy.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$37.64 |
Daily Change: | -0.25 -0.66 |
Daily Volume: | 991,631 |
Market Cap: | US$6.510B |
April 30, 2025 April 30, 2025 April 23, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load